January 23rd 2024
Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
December 26th 2023
We estimated the long-term risks and benefits of disease modifying therapies. Benefits were favored by natalizumab with minimal increased risks in the negative anti-JC virus population.
Read More
Matthias Cheung, PhD, FCSHP, FASHP, a principal at Advanced Rx Consulting, LLC, and an adjunct professor of pharmacy practice at the University of the Pacific, Thomas J. Long School of Pharmacy and Health Services, discusses the circumstances and factors that catalyzed the passage of current legislation and regulatory policies for orphan drugs, rare diseases, and ultra-rare diseases.
Read More
Pediatric Integrated Delivery System's Experience With Pandemic Influenza A (H1N1)
Experience of a pediatric integrated delivery system with the surge from the 2009 H1N1 pandemic is described, emphasizing scale, scope, and flexibility at multiple locations.
Read More
Influence of Patient Preferences on the Cost-Effectiveness of Screening for Lynch Syndrome
This cost-utility analysis reports on the effect of quality of life on the value of screening all new patients with colorectal cancer for Lynch Syndrome.
Read More
TSI Assay Utilization: Impact on Costs of Graves' Hyperthyroidism Diagnosis
January 16th 2012An evidence-based managed care budget impact model shows that incorporating TSI testing into existing Graves%u2019 disease hyperthyroidism diagnostic algorithms reduces costs and shortens time to diagnosis.
Read More